Precipio, Inc. PRPO
We are a healthcare biotechnology company with a mission to battle the systemic problem of disease misdiagnosis, by focusing on improving cancer diagnostics, particularly, hematologic malignancies. Our objective is to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation. We aim to achieve this through a combination of clinical laboratory services and proprietary diagnostic product development. By integrating diagnostic services with product development, our service business doubles as a self-funded research and development ("R&D") unit, enabling us to achieve rapid and cost-efficient innovation rather than being a major cost center for us.
Last close
20.01
2026-10-23
Market cap
$35.8M
2026-06-30 share count
52-week range
18.50 - 33.63
Valuation FY2025 figures against the last close
P/S1.5x
P/E—
P/FCF99.8x
EV/EBITDA773.2x
Dividend yield—
Diluted EPS-0.23
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.2M | $18.6M | $15.4M | $9.8M | $8.7M | $7.4M | $4.1M | $3.4M | $2.0M | $1.7M |
| Cost of revenue | $13.3M | $11.0M | $9.2M | $6.9M | $6.5M | $4.9M | $2.9M | $2.6M | $1.4M | $970.0K |
| Gross profit | $10.7M | $7.6M | $6.0M | $2.5M | $2.4M | $1.1M | $219.0K | $225.0K | $292.0K | $753.0K |
| R&D | $1.6M | $1.3M | $1.7M | $1.7M | $1.3M | $1.2M | $1.2M | $1.1M | $500.0K | $0 |
| SG&A | — | — | — | — | — | $10.3M | $9.6M | $9.5M | $6.5M | $2.5M |
| Total operating expenses | $11.9M | $11.8M | $13.6M | $15.3M | $12.0M | $10.3M | $11.2M | $14.1M | $15.8M | $2.5M |
| Operating income | -$1.2M | -$4.2M | -$7.6M | -$12.8M | -$9.6M | -$9.1M | -$11.0M | -$13.9M | -$15.5M | -$1.7M |
| Pre-tax income | -$363.0K | -$4.3M | -$5.9M | -$12.2M | -$8.5M | -$10.6M | -$13.3M | -$16.0M | -$20.7M | -$2.2M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $70.0K | $279.0K | $349.0K | $0 |
| Net income | -$363.0K | -$4.3M | -$5.9M | -$12.2M | -$8.5M | -$10.6M | -$13.2M | -$15.7M | -$20.7M | -$2.2M |
| EPS, basic | -0.23 | -2.93 | -4.51 | -10.73 | -0.40 | -0.85 | — | — | — | — |
| EPS, diluted | -0.23 | -2.93 | -4.51 | -10.73 | -0.40 | -0.85 | -2.33 | -13.82 | -7.16 | -9.44 |
| Shares, diluted (wtd. avg.) | 1.6M | 1.5M | 1.3M | 1.1M | 21.1M | 16.5M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.7M | $1.4M | $1.5M | $3.4M | $11.7M | $2.7M | $848.0K | $381.0K | $421.0K | $51.0K |
| Receivables | $2.0M | $799.0K | $1.3M | $1.0M | $697.0K | $874.0K | $574.0K | $690.0K | $730.0K | $388.0K |
| Inventory | $935.0K | $724.0K | $384.0K | $708.0K | $564.0K | $350.0K | $184.0K | $197.0K | $161.0K | $100.0K |
| Total current assets | $6.0M | $3.5M | $3.7M | $5.7M | $13.5M | $4.2M | $1.9M | $1.8M | $1.7M | $552.0K |
| Property, plant and equipment | $729.0K | $719.0K | $739.0K | $877.0K | $836.0K | $277.0K | $431.0K | $496.0K | $353.0K | $280.0K |
| Goodwill | — | — | — | — | — | — | — | — | $4.7M | — |
| Other intangibles | $10.9M | $11.9M | $12.8M | $13.8M | $14.7M | $15.7M | $16.7M | $19.3M | $20.5M | $562.0K |
| Total assets | $21.3M | $17.0M | $18.1M | $21.5M | $30.4M | $20.7M | $19.5M | $21.6M | $27.3M | $842.0K |
| Accounts payable | $1.1M | $618.0K | $622.0K | $2.0M | $1.9M | $1.7M | $1.9M | $5.2M | $5.1M | $1.1M |
| Short-term debt | $30.0K | $297.0K | $235.0K | $255.0K | $26.0K | $648.0K | $321.0K | $263.0K | $587.0K | $395.0K |
| Total current liabilities | $3.8M | $4.3M | $3.1M | $4.4M | $4.2M | $4.7M | $4.3M | $13.8M | $10.0M | $3.0M |
| Long-term debt | $47.0K | $77.0K | $106.0K | $134.0K | $160.0K | $362.0K | $198.0K | $253.0K | $2.8M | $4.1M |
| Total liabilities | $6.8M | $4.9M | $3.7M | $5.1M | $5.8M | $6.6M | $6.3M | $15.5M | $14.2M | $7.3M |
| Retained earnings | -$102.8M | -$102.4M | -$98.2M | -$92.3M | -$80.1M | -$71.6M | -$60.9M | -$47.7M | -$31.5M | -$10.8M |
| Total equity | $14.6M | $12.1M | $14.4M | $16.4M | $24.6M | $14.2M | $13.2M | $6.1M | $13.0M | -$6.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $685.0K | $439.0K | -$3.6M | -$7.7M | -$6.6M | -$7.4M | -$9.1M | -$6.8M | -$6.7M | -$959.0K |
| Depreciation and amortisation | $1.2M | $1.2M | $1.2M | $1.2M | $1.1M | $1.1M | $1.1M | $1.3M | $743.0K | $112.0K |
| Stock-based compensation | $1.2M | $1.5M | $1.6M | $3.8M | $1.9M | $703.0K | $668.0K | $529.0K | $49.0K | $12.0K |
| Capital expenditure | $326.0K | $223.0K | $126.0K | $277.0K | $682.0K | $151.0K | $55.0K | $97.0K | $143.0K | $19.0K |
| Investing cash flow | -$326.0K | -$223.0K | -$126.0K | -$277.0K | -$682.0K | -$96.0K | -$55.0K | -$97.0K | -$42.0K | $1.0M |
| Financing cash flow | $903.0K | -$329.0K | $1.7M | -$225.0K | $16.3M | $9.3M | $9.7M | $6.8M | $7.1M | $775.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-017462.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $2.0M | $3.4M | $4.1M | $7.4M | $8.7M | $9.8M | $15.4M | $18.6M | $24.2M |
| Gross profit | $753.0K | $292.0K | $225.0K | $219.0K | $1.1M | $2.4M | $2.5M | $6.0M | $7.6M | $10.7M |
| Net income | -$2.2M | -$20.7M | -$15.7M | -$13.2M | -$10.6M | -$8.5M | -$12.2M | -$5.9M | -$4.3M | -$363.0K |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Shareholder vote Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $48.79B | 37.9x | 6.7% |
| WAT | WATERS CORP /DE/ | $44.57B | 42.2x | 7.0% |
| ILMN | ILLUMINA, INC. | $40.68B | 49.4x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $33.47B | 39.7x | 4.0% |
| RVTY | REVVITY, INC. | $17.72B | 76.7x | 3.7% |
| AVTR | Avantor, Inc. | $11.80B | — | -3.4% |
| BIO | BIO-RAD LABORATORIES, INC. | $9.89B | 13.3x | 0.7% |
| TXG | 10x Genomics, Inc. | $9.30B | — | 5.2% |